Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | What to look forward to in urothelial cancer at ASCO GU 2023

Arlene Siefker-Radtke • 16 Feb 2023
GU Cancers 2023
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses what to look out for at the ASCO GU Cancers Symposium 2023, including data on whether adjuvant immunotherapy should be administered in the perioperative space. The current data suggests the use of adjuvant nivolumab only delays tumor recurrence, however, Dr Siefker-Radtke is hoping to see long-term data suggestive of cure or long-term benefit. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arlene Siefker-Radtke

Current limitations and research on molecular subtyping in the treatment of urothelial carcinoma
1:11
Current limitations and research on molecular subtyping in the treatment of urothelial carcinoma
Arlene Siefker-Radtke • 31 May 2024
THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab
1:49
THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab
Arlene Siefker-Radtke • 31 May 2024
The role of enfortumab vedotin in urothelial cancer treatment
1:18
The role of enfortumab vedotin in urothelial cancer treatment
Arlene Siefker-Radtke • 31 May 2024
Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC
1:13
Phase III TROPICS-04 trial: sacituzumab govitecan vs treatment of choice in advanced mUC
Arlene Siefker-Radtke • 31 May 2024

Related Videos

Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
1:55
Decipher score predicts metastasis risk and abiraterone benefit in prostate cancer
Sarah Howlett • 26 Oct 2026
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:20
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
2:24
The evolving role of EV plus immunotherapy in muscle-invasive bladder cancer
Jens Bedke • 26 Oct 2026
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
2:58
EV-303: long-term subgroup outcomes with EV and pembrolizumab in la/mUC
Jens Bedke • 26 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals